There are compelling theoretical reasons for early therapeutic intervention in HIV-1 infection, for this might either eliminate HIV-1 from the body completely, or lower the virological setpoint with subsequentl clinical benefit. Encouraging results from combination treatment of chronically infected patients provide a therapeutic rationale for intervention in acute and early HIV-1 infection. We plan to test combination therapy, as part of the Acute Infection and Early Disease Research Network. We propose to continue two current triple-drug trials (AZT/3TC/ritonavir/saquinavir and AZT/3TC/indinavir), and to commence at least two new trials involving four drugs (AZT/3TC/ritonavir/saquinavir and AZT/3TC/GW141/GW1592). Already, we have achieved consistent, sustained reductions in plasma viremia to <500 HIV-1 RNA copies/ml, and we will use improved assays sensitive down to 25 copies/ml to estimate the extent of viremia reduction more precisely. Some patients with persistently undetectable viremia will be offered lymphatic tissue and rectal biopsies, and genital fluid analysis, for examination on ongoing viral relication. The option to discontinue therapy will be offered based on virologic results. If virus re-emerges after cessation of treatment, or during therapy, breakthorugh virus will be characterized genotypically and phenotypically. We will also monitor cellular and humoral immune responses, to assess how reductions in viral antigen load influence the development and maintenance of effector and memory T-cell and B-cell responses. We have detected signs of antibod seroreversion, but some CTL responses persist. I may be important for treated patients to develop HIV-1 memory responses, to enable them to suppress residual virus replication permanently. To assess when immune memory develops, we will use precusor frequency assays in vitro, and determine whether anamnestic responses to HIV-1 antigens can be stimulated in vivo. We will expand our existing facilities for banking and storage of speciments, and continue to support novel therapeutic interventions in acute and/or early HIV-1 infection within the framework of the established network.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI041534-04S1
Application #
6465299
Study Section
Special Emphasis Panel (ZAI1 (M1))
Program Officer
Batzold, Frederick
Project Start
1997-07-01
Project End
2002-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
4
Fiscal Year
2001
Total Cost
$1,020,826
Indirect Cost
Name
Aaron Diamond AIDS Research Center
Department
Type
DUNS #
786658872
City
New York
State
NY
Country
United States
Zip Code
10016
Moore, Camille M; MaWhinney, Samantha; Forster, Jeri E et al. (2017) Accounting for dropout reason in longitudinal studies with nonignorable dropout. Stat Methods Med Res 26:1854-1866
Mohri, Hiroshi; Prada, Nicole; Markowitz, Martin (2015) Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant. J Acquir Immune Defic Syndr 68:487-94
Markowitz, Martin; Evering, Teresa H; Garmon, Donald et al. (2014) A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr 66:140-7
Hogan, Christine M; Degruttola, Victor; Sun, Xin et al. (2012) The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 205:87-96
Evering, Teresa H; Mehandru, Saurabh; Racz, Paul et al. (2012) Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 8:e1002506
Castor, Delivette; Low, Andrea; Evering, Teresa et al. (2012) Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr 61:1-8
Hecht, Frederick M; Wellman, Robert; Busch, Michael P et al. (2011) Identifying the early post-HIV antibody seroconversion period. J Infect Dis 204:526-33
Meditz, Amie L; MaWhinney, Samantha; Allshouse, Amanda et al. (2011) Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis 203:442-51
Li, Hui; Bar, Katharine J; Wang, Shuyi et al. (2010) High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog 6:e1000890
Miura, Toshiyuki; Brumme, Zabrina L; Brockman, Mark A et al. (2010) Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 84:7581-91

Showing the most recent 10 out of 60 publications